Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer

الملخص EN

Background : angiogenesis is an essential process in cancer growth maintenance, and metastasis.

Angiopoietin-2 promotes tumor angiogenesis by priming the vasculature and potentiating the effects of cytokines at the front of active neovascularization.

Enhanced expression of angiopoietin-2 has been reported in lung cancer tissue.

Surviving is one of the inhibitors of apoptosis protein that has been shown to play a key role in cancer progression, and in tumor angiogenesis.

Also plays a key role in tumor cell resistance to anticancer agents and ionizing radiation.

Aim : to measure the serum levels of angiopoietin-2 and surviving as possible antigenic factors in lung cancer patients with the assessment of their interrelationships and clinical significance.

Patients and methods: Patients with lung cancer as NSCLC (n= 70) and healthy volunteers (n= 10) were enrolled.

Serum angiopoietin-2 and surviving concentrations were measured using enzyme-linked immunosorbent assay (ELIZA).

Results : Median serum angiopoietin-2 levels with lung cancer (2730 pg / mL) ranged from 1171 to 6541 pg / mL was higher than the median of the control group (1795 pg / mL) ranged from 1076 to 2730 / mL, p< 0.001.

Median serum surviving levels were also higher in patients with lung cancer (35.0 pg / mL) ranged from 39.3 to 96.3 pg / mL than the median of the control group (48.8 pg / mL) ranged from 38.0 to 74.6 pg / mL, but did not reach statistical significance p = 0.206.

In all patients with lung cancer, serum angiopoietin-2 was not significantly correlated with surviving (r = 0.073, p = 0.657).

Neither serum angiopoietin-2 nor surviving showed significant relation with the serum angiopoietin-2 or surviving levels depending on the cell types, stage progression, and metastasis among the patients with NSCLC.

Conclusions : our study suggests that serum angiopoietin-2 is a useful marker for the diagnosis of NSCLC by ELIZA technique.